Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
STM-PHARM (СТМФАРМ) is a Russian pharmaceutical company founded in 2014, specializing in the development, production, and distribution of a wide range of healthcare products, including medicines, dietary supplements, cosmetics, and medical devices. Originally established as a division of the Pharmaimpeks pharmacy chain, the company now operates independently and utilizes a contract manufacturing model with over 20 production sites across Russia, Europe, and Asia. Its extensive portfolio of over 600 products includes well-known brands such as Maxiflor (probiotics), Livesil (hepatoprotectors), and Trineuro (neurology). STM-PHARM focuses on therapeutic areas such as gastroenterology, neurology, phlebology, and respiratory health, supplying products to more than 20,000 pharmacies and major online marketplaces. The company maintains a strong focus on quality, selecting manufacturing partners certified under GMP, ISO, and FDA standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on СТМФАРМ.